Speculate a takeover? 8 new licences recently awarded, or maybe news ref convertible bonds?? Speculation, speculation.....interesting though. but not that interesting if it goes down!!
just suspended!
The Financial Services Authority ('the FSA') temporarily suspends the securities set out below from the Official List effective from 19/11/2008 2:30pm at the request of the company pending an announcement:
Just to let you know that value_investor stated earlier, "Someone's bought 1.86 million shares at 0.35p today. Is that your creatures? The other two trades have been deleted."....I'll be sure to keep you up to date with this losers ramping attempts
Beyondme - MarketMakers; Google it
Value_investor - "results due out this week" In my opinion, he's talking sh*te and has desperately been trying to ramp this stock for weeks. The bottom line is there's no volume here. If this stock goes up you've blagged it well. Congratulations 50/50. 95 posts int the last 30days. 77 for Capt....."watch out, Beadle's about"
Placing -
NextGen is pleased to announce that it has placed 210,000,000 ordinary shares of £0.001 each (the 'Placing Shares') with two existing shareholders of the Company (the 'Placing'). The Placing Shares are to be issued at £0.0015 per share to raise £315,000
So the company proposes to pay £30m to shareholders by way of aTender Offer then consolidate shares 1 for 20. There are a few outstanding details namely; What is the minimum and maximum amount of shares a shareholder can put up for Tender? When will it happen? And of course at what price!?
First half of 2008 revenue at £56.0m (2007: £56.0m)
Operating profit up by 26% at £4.9m (2007: £3.9m)
Overall the Group's pre-tax profit has grown to £4.2m (2007: £1.0m)
The statutory loss attributable to equity holders was £11.9m (2007: £41.6m).
Not good....
On July 31, 2008, Biogen Idec Inc. and Elan Corporation, plc notified relevant
regulatory agencies of two confirmed cases of
progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated
with TYSABRI® in the commercial setting.
http://www.advfn.com/p.php?pid=nmona&cb=1217580379&article=27582945
Financial Highlights (unaudited)
*
Q2 revenue up 107% to $10.4 million (2007: $5.0 million)
*
H1 revenue up 98% to $19.5 million (2007: $9.9 million)
*
Food Safety sales up 188% to $10.8 million (2007: $3.8 million)
*
Endoscopy sales up 43% to $8.4 million (2007: $5.8 million)
*
Operating expenses for the first half 2008 expected to be approximately 8-10% below the same period last year
Operational Highlights
*
$11 million Sterilox Food Safety contract announced with top-five US supermarket
*
$8.6 million contract extension awarded from PuriCore's largest existing Sterilox Food Safety customer, a top-five US supermarket
*
$2.5 million contract extension awarded from one of PuriCore's largest Sterilox Food Safety customers (see separate announcement today)
*
Sterilox Solution demonstrated to be highly effective against pandemic H5N1 avian influenza
*
Sterilox Solution approved for organic food production, processing and handling
Balance Sheet
*
$9 million in cash as at 30 June 2008
*
Debt reduced by $3.4 million in the six months ended 30 June 2008
*
Placing raising £6 million with an Open Offer to raise up to an additional £4 million to fund the Company's growth (see separate announcement today)